CMAX Clinical Research
Adelaide, South Australia, 5000, Australia
NCT Number: NCT05012423
A Phase 1, Single-Center, Randomized, Double-Blind, Placebo-Controlled, Single And Multiple Ascending Dose, First-Time-In-Human Study to Assess The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ECC0509 in Healthy Volunteers.
Looking for future studies?
Notify Me18 year–65 year
All sexes
Interventional
Phase 1
Adelaide, South Australia, 5000, Australia
This study will be conducted in up to seven cohorts of Single Ascending Dose (SAD) & 3 cohorts of Multiple Ascending Dose (MAD). SAD will consist of a staggered dosing approach with a dose range from 1mg to 80mg. Staggered dosing approach will not be deployed for MAD cohorts with a dose range of 8mg to 40mg. In the MAD cohort, the effect of food will also be assessed by comparing the PK profile of Day 10 fed conditions against Day 14 fasted conditions.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Key Inclusion Criteria:
Key Exclusion Criteria:
Matching Placebo will be administered as oral capsules.
ECC0509 1 mg and 10 mg capsules. ECC0509 will be administered as oral capsules.
Time frame: SAD: Up to Day 8. MAD: Up to Day 21.
Safety Assessment evaluated through adverse events, laboratory evaluations, vital signs, ECGs, and physical examination.
Time frame: SAD: Up to Day 8.
Apparent clearance
Time frame: SAD: Up to Day 8.
Apparent volume of distribution
Time frame: MAD: Up to Day 21
Area under the concentration-time curve from time zero to time 24 hours
Time frame: MAD: Up to Day 21
Maximal observed concentration at steady-state
Time frame: MAD: Up to Day 21
Time when the maximal concentration is observed at steady-state
Time frame: MAD: Up to Day 21
Time prior to the first measurable (non-zero) concentration at steady-state
Time frame: SAD: Up to Day 8. MAD: Up to Day 21
Maximal observed concentration
Time frame: SAD: Up to Day 8. MAD: Up to Day 21
Time when the maximal concentration is observed
Time frame: SAD: Up to Day 8. MAD: Up to Day 21
Area under the curve up to the last quantifiable time-point
Time frame: MAD: Up to Day 21
Minimal observed concentration at steady-state
Time frame: SAD: Up to Day 8. MAD: Up to Day 21
Terminal elimination half-life
Time frame: SAD: Up to Day 8. MAD: Up to Day 21
Terminal elimination rate constant
Time frame: MAD: Up to Day 21
Apparent body clearance at steady-state
Time frame: MAD: Up to Day 21
Apparent volume of distribution at steady-state
Time frame: MAD: Up to Day 21
Area under the concentration-time curve for one dosing interval (τ) at steady state.
Time frame: SAD: Up to Day 8. MAD: Up to Day 21
Area under the concentration-time curve from time zero to infinity
Time frame: SAD: Up to Day 8. MAD: Up to Day 21
Percentage of AUC0-inf due to extrapolation from the time of the last observed concentration to infinity
Time frame: SAD: Up to Day 8. MAD: Up to Day 21.
plasma semicarbazide-sensitive amine oxidase (SSAO) activity.
Eccogene
Industry
A Phase 1, Single-Center, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose, First-Time-In-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ecc0509 in Healthy Volunteers
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04801849
Digestive System Diseases, Fatty Liver
La Jolla, California, United States
View Trial DetailsNCT02815891
Digestive System Diseases, Fatty Liver
Phoenix, Arizona, United States
View Trial DetailsNCT05877547
Digestive System Diseases, Fatty Liver
Chandler, Arizona, United States
View Trial DetailsNCT04971785
Digestive System Diseases, Fatty Liver
Birmingham, Alabama, United States
View Trial Details